PURPOSE: Experimental evidence suggests that anticoagulants (ACs) may inhibit cancer growth and metastasis, but clinical data have been limited. We investigated whether use of ACs was associated with the risk of death from prostate cancer. PATIENTS AND METHODS: This study comprised 5,955 men in the Cancer of the Prostate Strategic Urologic Research Endeavor database with localized adenocarcinoma of the prostate treated with radical prostatectomy (RP) or radiotherapy (RT). Of them, 2,175 (37%) were receiving ACs (warfarin, clopidogrel, enoxaparin, and/or aspirin). The risk of prostate cancer-specific mortality (PCSM) was compared between the AC and non-AC groups. RESULTS: After a median follow-up of 70 months, risk of PCSM was significantly lower in the AC group compared with the non-AC group (3% v 8% at 10 years; P < .01). The risks of disease recurrence and bone metastasis were also significantly lower. In a subgroup analysis by clinical risk category, the reduction in PCSM was most prominent in patients with high-risk disease (4% v 19% at 10 years; P < .01). The benefit from AC was present across treatment modalities (RT or RP). Analysis by type of AC medication suggested that the PCSM reduction was primarily associated with aspirin. Multivariable analysis indicated that aspirin use was independently associated with a lower risk of PCSM (adjusted hazard ratio, 0.43; 95% CI, 0.21 to 0.87; P = .02). CONCLUSION: AC therapy, particularly aspirin, was associated with a reduced risk of PCSM in men treated with RT or RP for prostate cancer. The association was most prominent in patients with high-risk disease.
PURPOSE: Experimental evidence suggests that anticoagulants (ACs) may inhibit cancer growth and metastasis, but clinical data have been limited. We investigated whether use of ACs was associated with the risk of death from prostate cancer. PATIENTS AND METHODS: This study comprised 5,955 men in the Cancer of the Prostate Strategic Urologic Research Endeavor database with localized adenocarcinoma of the prostate treated with radical prostatectomy (RP) or radiotherapy (RT). Of them, 2,175 (37%) were receiving ACs (warfarin, clopidogrel, enoxaparin, and/or aspirin). The risk of prostate cancer-specific mortality (PCSM) was compared between the AC and non-AC groups. RESULTS: After a median follow-up of 70 months, risk of PCSM was significantly lower in the AC group compared with the non-AC group (3% v 8% at 10 years; P < .01). The risks of disease recurrence and bone metastasis were also significantly lower. In a subgroup analysis by clinical risk category, the reduction in PCSM was most prominent in patients with high-risk disease (4% v 19% at 10 years; P < .01). The benefit from AC was present across treatment modalities (RT or RP). Analysis by type of AC medication suggested that the PCSM reduction was primarily associated with aspirin. Multivariable analysis indicated that aspirin use was independently associated with a lower risk of PCSM (adjusted hazard ratio, 0.43; 95% CI, 0.21 to 0.87; P = .02). CONCLUSION: AC therapy, particularly aspirin, was associated with a reduced risk of PCSM in men treated with RT or RP for prostate cancer. The association was most prominent in patients with high-risk disease.
Authors: Mack Roach; Gerald Hanks; Howard Thames; Paul Schellhammer; William U Shipley; Gerald H Sokol; Howard Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2006-07-15 Impact factor: 7.038
Authors: Mark H Kawachi; Robert R Bahnson; Michael Barry; J Erik Busby; Peter R Carroll; H Ballentine Carter; William J Catalona; Michael S Cookson; Jonathan I Epstein; Ruth B Etzioni; Veda N Giri; George P Hemstreet; Richard J Howe; Paul H Lange; Hans Lilja; Kevin R Loughlin; James Mohler; Judd Moul; Robert B Nadler; Stephen G Patterson; Joseph C Presti; Antoinette M Stroup; Robert Wake; John T Wei Journal: J Natl Compr Canc Netw Date: 2010-02 Impact factor: 11.908
Authors: Michelle D Holmes; Wendy Y Chen; Lisa Li; Ellen Hertzmark; Donna Spiegelman; Susan E Hankinson Journal: J Clin Oncol Date: 2010-02-16 Impact factor: 44.544
Authors: Jack Cuzick; Florian Otto; John A Baron; Powel H Brown; John Burn; Peter Greenwald; Janusz Jankowski; Carlo La Vecchia; Frank Meyskens; Hans Jörg Senn; Michael Thun Journal: Lancet Oncol Date: 2009-05 Impact factor: 41.316
Authors: Ozge Uluçkan; Mark C Eagleton; Desiree H Floyd; Elizabeth A Morgan; Angela C Hirbe; Matthew Kramer; Nikki Dowland; Julie L Prior; David Piwnica-Worms; Soon Seog Jeong; Ridong Chen; Katherine Weilbaecher Journal: J Cell Biochem Date: 2008-07-01 Impact factor: 4.429
Authors: Cindy Ke Zhou; Sarah E Daugherty; Linda M Liao; Neal D Freedman; Christian C Abnet; Ruth Pfeiffer; Michael B Cook Journal: Cancer Prev Res (Phila) Date: 2017-05-15
Authors: David C Qian; Jinyoung Byun; Younghun Han; Casey S Greene; John K Field; Rayjean J Hung; Yonathan Brhane; John R Mclaughlin; Gordon Fehringer; Maria Teresa Landi; Albert Rosenberger; Heike Bickeböller; Jyoti Malhotra; Angela Risch; Joachim Heinrich; David J Hunter; Brian E Henderson; Christopher A Haiman; Fredrick R Schumacher; Rosalind A Eeles; Douglas F Easton; Daniela Seminara; Christopher I Amos Journal: Hum Mol Genet Date: 2015-10-19 Impact factor: 6.150
Authors: Cheryl Jacobs Smith; Tiffany H Dorsey; Wei Tang; Symone V Jordan; Christopher A Loffredo; Stefan Ambs Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-03-14 Impact factor: 4.254
Authors: Corbin D Jacobs; Stephen G Chun; Jingsheng Yan; Xian-Jin Xie; David A Pistenmaa; Raquibul Hannan; Yair Lotan; Claus G Roehrborn; Kevin S Choe; D W Nathan Kim Journal: Cancer Biol Ther Date: 2014-03-21 Impact factor: 4.742